L V dUscio
Overview
Explore the profile of L V dUscio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
dUscio L, Luscher T
Curr Hypertens Rep
. 2001 Nov;
3 Suppl 2:S6-14.
PMID: 11716800
Vasopeptidase inhibitors are a new class of drugs capable of inhibiting both angiotensin-converting enzyme and neutral endopeptidase 24.11. This involves simultaneous inhibition with a single molecule of two key enzymes,...
2.
dUscio L, Smith L, Katusic Z
Stroke
. 2001 Nov;
32(11):2658-64.
PMID: 11692031
Background And Purpose: The effects of Western-type fat diet on endothelium-dependent relaxations and vascular structure in carotid arteries from a mouse model of human atherosclerosis are not known. Our objective...
3.
dUscio L, Baker T, Mantilla C, Smith L, Weiler D, Sieck G, et al.
Arterioscler Thromb Vasc Biol
. 2001 Jun;
21(6):1017-22.
PMID: 11397713
Endothelium-dependent relaxations mediated by NO are impaired in a mouse model of human atherosclerosis. Our objective was to characterize the mechanisms underlying endothelial dysfunction in aortas of apolipoprotein E (apoE)-deficient...
4.
Quaschning T, dUscio L, Shaw S, Viswambharan H, Ruschitzka F, Luscher T
Nephrol Dial Transplant
. 2001 Jun;
16(6):1176-82.
PMID: 11390717
Background: Vasopeptidase inhibition (VPI) represents a new therapeutic principle including both inhibition of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP). The present study investigated the effect of the vasopeptidase inhibitor...
5.
Quaschning T, dUscio L, Shaw S, Luscher T
Hypertension
. 2001 Apr;
37(4):1108-13.
PMID: 11304511
Omapatrilat represents a new class of drugs capable of inhibiting both ACE and neutral endopeptidase 24.11, the so-called vasopeptidase inhibitors. It therefore contributes to neurohumoral modulation, which might improve endothelial...
6.
Barton M, Carmona R, Krieger J, Goettsch W, Morawietz H, dUscio L, et al.
J Cardiovasc Pharmacol
. 2000 Nov;
36(5 Suppl 1):S244-7.
PMID: 11078388
Using the orally active endothelin-A- (ET(A)) receptor antagonist LU135252, we determined whether endothelin-1 (ET-1) and/or dietary fat may be involved in angiotensin-converting enzyme (ACE) regulation in vivo. In C57BL6/J mice,...
7.
Barton M, Lattmann T, dUscio L, Luscher T, Shaw S
J Cardiovasc Pharmacol
. 2000 Nov;
36(5 Suppl 1):S153-6.
PMID: 11078364
Aging is an independent risk factor for cardiovascular and renal disease. The study reported here investigated whether aging affects endothelin-1 (ET-1) and tissue levels of the nitric oxide metabolites nitrite/nitrate...
8.
dUscio L, Barton M, Shaw S, Luscher T
J Cardiovasc Pharmacol
. 2000 Sep;
35(4 Suppl 2):S55-59.
PMID: 10976783
Endothelin (ET)-1, a potent vasoconstrictor peptide, is primarily released abluminally from endothelial cells and exerts its biological effect through the activation of specific ET receptors. Endothelin subtype A receptors (ET(A))...
9.
Altwegg L, dUscio L, Barandier C, Cosentino F, Yang Z, Luscher T
J Cardiovasc Pharmacol
. 2000 Sep;
36(3):316-20.
PMID: 10975588
Nebivolol is a newer beta1-selective adrenergic receptor antagonist, which unlike classic beta-blockers, lowers systemic vascular resistance by direct vasodilator effects possibly involving NO. This study was designed to determine the...
10.